In contrast, 9-ING-41 markedly reduced the growth rate of the CRC organoids from Patient 1 by 44%–62% both alone (p < .05) and in combination with the tested SoC drugs (p < .05). This evidence concerns the gene UBXN11 and colorectal carcinoma.